JPWO2020014366A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020014366A5 JPWO2020014366A5 JP2021500519A JP2021500519A JPWO2020014366A5 JP WO2020014366 A5 JPWO2020014366 A5 JP WO2020014366A5 JP 2021500519 A JP2021500519 A JP 2021500519A JP 2021500519 A JP2021500519 A JP 2021500519A JP WO2020014366 A5 JPWO2020014366 A5 JP WO2020014366A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polypeptide
- isolated nucleic
- seq
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 59
- 229920001184 polypeptide Polymers 0.000 claims description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 30
- 239000012642 immune effector Substances 0.000 claims description 29
- 229940121354 immunomodulator Drugs 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 230000011664 signaling Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 102000001301 EGF receptor Human genes 0.000 claims description 11
- 108060006698 EGF receptor Proteins 0.000 claims description 11
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 10
- 108020001756 ligand binding domains Proteins 0.000 claims description 10
- 108020004017 nuclear receptors Proteins 0.000 claims description 10
- 102000006255 nuclear receptors Human genes 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 125000006850 spacer group Chemical group 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 230000004568 DNA-binding Effects 0.000 claims description 4
- 241001648840 Thosea asigna virus Species 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 240000007019 Oxalis corniculata Species 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 101150095442 Nr1h2 gene Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024022330A JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696075P | 2018-07-10 | 2018-07-10 | |
| US62/696,075 | 2018-07-10 | ||
| PCT/US2019/041213 WO2020014366A1 (en) | 2018-07-10 | 2019-07-10 | Ror-1 specific chimeric antigen receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022330A Division JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530217A JP2021530217A (ja) | 2021-11-11 |
| JPWO2020014366A5 true JPWO2020014366A5 (enExample) | 2022-07-12 |
Family
ID=69141807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500519A Pending JP2021530217A (ja) | 2018-07-10 | 2019-07-10 | Ｒｏｒ−１特異的キメラ抗原受容体およびその使用 |
| JP2024022330A Pending JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022330A Pending JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12275772B2 (enExample) |
| EP (1) | EP3820484A4 (enExample) |
| JP (2) | JP2021530217A (enExample) |
| KR (1) | KR20210043562A (enExample) |
| CN (1) | CN112714769A (enExample) |
| AU (1) | AU2019301147A1 (enExample) |
| CA (1) | CA3105816A1 (enExample) |
| IL (1) | IL280029A (enExample) |
| SG (1) | SG11202100205UA (enExample) |
| WO (1) | WO2020014366A1 (enExample) |
| ZA (1) | ZA202100391B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2018352984B2 (en) * | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| JP2021530217A (ja) | 2018-07-10 | 2021-11-11 | プレシゲン，インコーポレイテッド | Ｒｏｒ−１特異的キメラ抗原受容体およびその使用 |
| JP7632868B2 (ja) * | 2018-10-26 | 2025-02-19 | 国立大学法人信州大学 | 高効率な遺伝子改変細胞の作製方法 |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| IL296511A (en) | 2020-03-20 | 2022-11-01 | Lyell Immunopharma Inc | Novel recombinant cell surface markers |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN113584083A (zh) * | 2020-04-30 | 2021-11-02 | 深圳市深研生物科技有限公司 | 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法 |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| EP4240405A1 (en) | 2020-11-05 | 2023-09-13 | Mendus B.V. | Use of tumor-independent antigens in immunotherapies |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| KR20230143140A (ko) * | 2021-01-11 | 2023-10-11 | 프레시전 인코포레이티드 | 키메라 수용체 요법 |
| CA3203705A1 (en) | 2021-01-22 | 2022-07-28 | Erik Hans MANTING | Methods of tumor vaccination |
| CA3210515A1 (en) * | 2021-02-01 | 2022-08-04 | The Regents Of The University Of California | Treatment of neuroendocrine cancers |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2022188652A1 (zh) * | 2021-03-09 | 2022-09-15 | 四川科伦博泰生物医药股份有限公司 | Ror1结合蛋白及其用途 |
| CN118613499A (zh) * | 2021-08-18 | 2024-09-06 | 宾夕法尼亚大学董事会 | 对b细胞受体特异的嵌合抗原受体的组合物和方法 |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| IL316226A (en) * | 2022-05-24 | 2024-12-01 | Caribou Biosciences Inc | Anti-ror1 antibody and ror1-targeting engineered cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN118206620A (zh) * | 2022-12-09 | 2024-06-18 | 上海细胞治疗集团股份有限公司 | 一种多肽标签及其应用 |
| CN116284246B (zh) * | 2022-12-12 | 2025-11-14 | 江苏三联生物工程股份有限公司 | 信号肽、核酸片段、重组表达载体、宿主细胞及其应用 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025194140A1 (en) * | 2024-03-15 | 2025-09-18 | Port Therapeutics, Inc. | Thermally controlled gene expression and uses thereof |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| CA2251466A1 (en) | 1996-04-05 | 1997-10-16 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| AU738494B2 (en) | 1997-07-10 | 2001-09-20 | Salk Institute For Biological Studies, The | Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| WO2011159847A2 (en) * | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| WO2012045085A1 (en) * | 2010-10-01 | 2012-04-05 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| DK2663579T3 (en) * | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| US9402919B2 (en) * | 2011-03-04 | 2016-08-02 | Intrexon Corporation | Vectors conditionally expressing protein |
| WO2013154760A1 (en) * | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| SG11201502816YA (en) * | 2012-10-12 | 2015-05-28 | Agency Science Tech & Res | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| KR102238226B1 (ko) | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| SG11201604781RA (en) | 2013-12-18 | 2016-07-28 | Intrexon Corp | Single chain il-12 nucleic acids, polypeptids, and uses thereof |
| BR112017001821A2 (pt) * | 2014-07-29 | 2017-11-21 | Cellectis | receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer |
| WO2016016343A1 (en) * | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| US20170291934A1 (en) | 2014-09-22 | 2017-10-12 | Charles C. Reed | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| NZ733841A (en) * | 2015-01-16 | 2024-01-26 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for ror1 |
| EP3298032A1 (en) * | 2015-05-18 | 2018-03-28 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
| AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| CA3012344A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11787848B2 (en) * | 2016-06-08 | 2023-10-17 | Precigen, Inc. | CD33 specific chimeric antigen receptors |
| WO2018102606A1 (en) * | 2016-11-30 | 2018-06-07 | Intrexon Corporation | Steroid administration and immunotherapy |
| CN110291200B (zh) * | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| KR20240128814A (ko) * | 2017-01-10 | 2024-08-27 | 프레시전 인코포레이티드 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| AU2018281316B2 (en) | 2017-06-07 | 2024-05-30 | Precigen, Inc. | Expression of novel cell tags |
| AU2018352984B2 (en) * | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| JP7607872B2 (ja) | 2018-03-30 | 2025-01-06 | ユニバーシティ オブ ジュネーブ | マイクロｒｎａ発現構築物及びその使用 |
| JP2021530217A (ja) | 2018-07-10 | 2021-11-11 | プレシゲン，インコーポレイテッド | Ｒｏｒ−１特異的キメラ抗原受容体およびその使用 |
-
2019
- 2019-07-10 JP JP2021500519A patent/JP2021530217A/ja active Pending
- 2019-07-10 KR KR1020217002650A patent/KR20210043562A/ko active Pending
- 2019-07-10 WO PCT/US2019/041213 patent/WO2020014366A1/en not_active Ceased
- 2019-07-10 EP EP19833113.4A patent/EP3820484A4/en active Pending
- 2019-07-10 CA CA3105816A patent/CA3105816A1/en active Pending
- 2019-07-10 CN CN201980059126.7A patent/CN112714769A/zh active Pending
- 2019-07-10 SG SG11202100205UA patent/SG11202100205UA/en unknown
- 2019-07-10 AU AU2019301147A patent/AU2019301147A1/en active Pending
-
2021
- 2021-01-07 IL IL280029A patent/IL280029A/en unknown
- 2021-01-07 US US17/143,386 patent/US12275772B2/en active Active
- 2021-01-19 ZA ZA2021/00391A patent/ZA202100391B/en unknown
-
2024
- 2024-02-16 JP JP2024022330A patent/JP2024073449A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020014366A5 (enExample) | ||
| US12410248B2 (en) | Chimeric antigen receptor and its use | |
| JP2024138280A5 (enExample) | ||
| JP7253020B2 (ja) | キメラ抗原受容体およびその使用 | |
| CN107109421B (zh) | Car表达载体及car表达t细胞 | |
| ES2905557T3 (es) | Receptor de antígeno quimérico anti-CD30 y su uso | |
| JP2019517267A5 (enExample) | ||
| TWI811278B (zh) | 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞 | |
| JP2024023232A5 (enExample) | ||
| US11370845B2 (en) | Anti-glypican-1-immunizing antigen receptor | |
| JP2020120660A (ja) | キメラ抗原受容体 | |
| CN115698081A (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
| CN111378625A (zh) | 一种cxcl13趋化型car－t细胞的制备和应用 | |
| WO2022029431A1 (en) | Chimeric receptor binding tgf-beta | |
| CN107475275A (zh) | 嵌合抗原受体及其表达基因、双抗原调节的嵌合抗原受体修饰的t细胞及其应用 | |
| JPWO2019236577A5 (enExample) | ||
| JP4635255B2 (ja) | 抗体医薬 | |
| EP4061385A1 (en) | A method for redesign and expansion of nk92 cells for use in immunotherapy | |
| JPWO2020163634A5 (enExample) | ||
| KR20240034205A (ko) | 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 | |
| CN107446937B (zh) | 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用 | |
| RU2023106937A (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения | |
| WO2025228249A1 (zh) | 一种工程化改造gpi锚定信号肽、其融合蛋白及应用 | |
| CN116102662A (zh) | 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用 | |
| RU2020142686A (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения |